Therapeutics News and Research

RSS

Halozyme grants Pfizer worldwide license to develop products combining Enhanze with biologics

Halozyme Therapeutics, Inc. announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. for the purpose of developing and commercializing products combining proprietary Pfizer biologics with Halozyme's Enhanze technology.

21 Dec 2012

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.

21 Dec 2012

Acorda Therapeutics acquires Neuronex

Acorda Therapeutics, Inc. today announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.

21 Dec 2012

Scientists design small molecules that recognize myotonic dystrophy-associated RNAs

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new approach to alter the function of RNA in living cells by designing molecules that recognize and disable RNA targets. As a proof of principle, in the new study the team designed a molecule that disabled the RNA causing myotonic dystrophy.

21 Dec 2012

Echo Therapeutics prices underwritten public offering of 3,200,000 shares of common stock

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the pricing of a previously announced underwritten public offering of 3,200,000 shares of its common stock, offered at a price to the public of $0.95 per share.

20 Dec 2012

Study identifies mechanisms responsible for regenerating blood vessels in the brain

New research from the University of Georgia identifies the mechanisms responsible for regenerating blood vessels in the brain.

20 Dec 2012

Hospital MRIs may effectively predict long-term outcomes for people with mild TBI

Hospital MRIs may be better at predicting long-term outcomes for people with mild traumatic brain injuries than CT scans, the standard technique for evaluating such injuries in the emergency room, according to a clinical trial led by researchers at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH).

19 Dec 2012

Jagaricin and antifungal drugs: an interview with Prof Christian Hertweck

Most people have already experienced a fungal infection (mycosis) of the outer layer of the skin, athlete’s foot or ringworm. Whereas such infections may be cumbersome and often difficult to cure, usually they are not dangerous. However, in cases where a fungus causes a systemic infection, this is, it infects internal organs such as lungs or brain, the infection may turn into a life-threatening disease. Of course, only pathogenic fungi cause problems and the degree of virulence varies.

18 Dec 2012

e-Therapeutics’ ETS2101 cancer trials on track

e-Therapeutics plc today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013.

18 Dec 2012

Allakos closes $32M Series A financing to develop antibody-based therapeutics

Allakos Inc. announced today that it has completed a $32 million Series A preferred stock financing led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander , PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors.

17 Dec 2012

ProMining Therapeutics, Roche to develop small molecule therapeutics for type 2 diabetes mellitus

ProMining Therapeutics, Ltd. today announced a new collaboration with Roche in the field of type 2 diabetes mellitus.

17 Dec 2012

Naurex announces completion of $38M Series B financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of a $38 million Series B financing led by new investor Baxter Ventures.

17 Dec 2012

LCSB, AxoGlia receive Michael J. Fox Foundation grant for Parkinson's project

AxoGlia Therapeutics SA, a biopharmaceutical company which drives the development of innovative neural stem/progenitor cell differentiation and neuroprotective therapeutics, today announced that it has been awarded a Rapid Response Innovative Award from The Michael J. Fox Foundation, for a project that is performed in collaboration with the Luxembourg Centre for Systems Biomedicine (LCSB).

15 Dec 2012

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

Researchers discover two-faced group of cells at work in human colon cancer

Northwestern Medicine researchers have discovered a "two-faced" group of cells at work in human colon cancer, with opposing functions that can suppress or promote tumor growth. These cells are a subset of T-regulatory (Treg) cells, known to suppress immune responses in healthy individuals.

14 Dec 2012

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the publication of data from its first-in-human Phase 1 study of its NDV-3 vaccine program in the journal Vaccine.

13 Dec 2012

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.

13 Dec 2012

Study shows how osteocalcin plays a significant role in bone strength

A new study from engineering researchers at Rensselaer Polytechnic Institute shows, for the first time, how the little-understood protein osteocalcin plays a significant role in the strength of our bones. The findings could lead to new strategies and therapeutics for fighting osteoporosis and lowering the risk of bone fracture.

11 Dec 2012

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Durata Therapeutics, Inc. today announced preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

11 Dec 2012

Spinal manipulations do not overstrain internal carotid artery

Chiropractic cervical spinal manipulations do not pose undue stress and strain on the internal carotid artery, researchers affirm.

11 Dec 2012

Therapeutics News and Research

Halozyme grants Pfizer worldwide license to develop products combining Enhanze with biologics

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

Acorda Therapeutics acquires Neuronex

Scientists design small molecules that recognize myotonic dystrophy-associated RNAs

Echo Therapeutics prices underwritten public offering of 3,200,000 shares of common stock

Study identifies mechanisms responsible for regenerating blood vessels in the brain

Hospital MRIs may effectively predict long-term outcomes for people with mild TBI

Jagaricin and antifungal drugs: an interview with Prof Christian Hertweck

e-Therapeutics’ ETS2101 cancer trials on track

Allakos closes $32M Series A financing to develop antibody-based therapeutics

ProMining Therapeutics, Roche to develop small molecule therapeutics for type 2 diabetes mellitus

Naurex announces completion of $38M Series B financing

LCSB, AxoGlia receive Michael J. Fox Foundation grant for Parkinson's project

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Researchers discover two-faced group of cells at work in human colon cancer

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Study shows how osteocalcin plays a significant role in bone strength

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Spinal manipulations do not overstrain internal carotid artery

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News